National Lung Screening Trial (NLST) Screening

OBJECTIVES:

• Compare whether screening with low-dose helical CT scan vs chest x-ray reduces lung cancer-specific mortality in participants who are at high risk for developing lung cancer.

OUTLINE:

NLST participants were randomized to either low-dose helical CT or chest x-ray in equal proportions. A total of 53,454 participants were enrolled (26,722 in low-dose CT and 26,732 in chest radiography) at 33 screening centers across the United States. Screening was offered three times (at baseline and two annual follow-up examinations). The primary endpoint of the study was lung cancer mortality. The study arms were compared with regard to overall mortality, lung cancer incidence, and screening-related complications.

All low-dose scanners and chest x-ray machines were certified for use and met NLST protocol requirements and American College of Radiology guidelines. Low-dose CT acquisitions and chest radiographs were interpreted by trained radiologists. Participants and their health care provider were informed of study examination results. Participants with abnormalities suspicious for lung cancer were contacted for information regarding diagnostic evaluation. Medical records were collected on diagnostic evaluation, medical complications, and initial treatment.

Participants were then contacted at least annually by mail or telephone.

The National Lung Screening Trial (NLST) represents the union of two NCI-sponsored efforts, the NCI Lung Screening Study and the American College of Radiology Imaging Network (ACRIN).

Inclusion criteria

• Age 55-74 years (pack-years = packs per day * years smoked)
• 30 or more pack-years of cigarette smoking history
• Former smokers: quit smoking within the previous 15 years
• Ability to lie on the back with arms raised over the head
• Signed informed consent form

Exclusion criteria

• Metallic implants or devices in the chest or back, such as pacemakers or Harrington fixation rods
• Treatment for, or evidence of, any cancer other than nonmelanoma skin cancer or carcinoma in situ (with the exception of transitional cell carcinoma in situ or bladder carcinoma in situ) in the 5 years prior to eligibility assessment
• History of lung cancer
• History of removal of any portion of the lung, excluding needle biopsy
• Requirement for home oxygen supplementation
• Participation in another cancer screening trial
• Participation in a cancer prevention study, other than a smoking cessation study
• Unexplained weight loss of more than 15 pounds in the 12 months prior to eligibility assessment
• Recent hemoptysis
• Pneumonia or acute respiratory infection treated with antibiotics in the 12 weeks prior to eligibility assessment
• Chest CT examination in the 18 months prior to eligibility assessment